Charting Residual Disease: From Molecular Markers to Liquid Biopsies

This workshop explores the expanding role of NGS-based measurable residual disease (MRD) testing across hematologic malignancies. The first presentation will highlight findings from a recent methods paper optimizing IGH NGS for detecting MRD in plasma cfDNA, followed by preliminary insights from a pilot study investigating plasma cfDNA clonality in NHL post-CAR-T and bone marrow transplant. The second speaker will discuss research studies using ultra-deep NGS-based tracking of FLT3-ITD and NPM1 mutations, including emerging data on the prognostic significance of MRD assessment in the peripheral blood of AML subjects undergoing bone marrow transplant in first complete remission. Join us to discuss advanced strategies for non-invasive disease monitoring.